Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trial.

Saved in:
Bibliographic Details
Title: Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trial.
Authors: Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Beck LA; Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA., Gooderham M; Probity Medical Research, Peterborough, Ontario, Canada, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, Queen's University, Kingston, Ontario, Canada., Murrell DF; Department of Dermatology, St. George Hospital Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Wiseman MC; Wiseman Dermatology Research, Waterloo, Ontario, Canada, SKiNWISE Dermatology, Winnipeg, Manitoba, Canada; Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Sørensen L; Biostatistics, LEO Pharma, Ballerup, Denmark., Jönsson PG; Medical department, LEO Pharma, Ballerup, Denmark., Stein-Gold L; Henry Ford Health System, Detroit, MI, USA.
Source: The British journal of dermatology [Br J Dermatol] 2026 Jul 22. Date of Electronic Publication: 2026 Jul 22.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2133
DOI:10.1093/bjd/ljag296